A therosclerosis is an inflammatory disease, 1,2 associated with multiple systemic risk factors, including hypercholesterolemia, hypertension, diabetes mellitus, smoking, and physical inactivity. [3] [4] [5] Despite the presence of these systemic risk factors, atherosclerosis preferentially occurs in specific focal regions of branched or curved arteries exposed to disturbed flow (d-flow), suggesting a potential interaction between hemodynamic conditions and systemic risk factors in atherogenesis. More specifically, d-flow induces endothelial inflammation, which may prime these arterial regions for atherogenesis in the presence of the aforementioned systemic risk factors. 1-5 Indeed, we have recently demonstrated that exposure of pristine, straight common carotid artery to d-flow by partial carotid ligation leads to rapid and robust atherosclerosis development in apolipoprotein E (ApoE) −/− mice fed a high-fat diet. 6,7 However, the underlying mechanisms by which these synergistic effects lead to initiation and progression of atherosclerosis are still unclear.
against atherosclerosis. 13, 14 These results clearly suggest the role of BMPs in vascular disease, but specific BMP receptors that mediate this effect are unknown. BMP actions are mediated by 2 different types of BMP receptors (BMPR): type I receptors (Alk1, Alk2, Alk3, and Alk6) and type II receptors (BMPRII, ActRIIa, and ActRIIb). 15, 16 On binding to BMPs, type I BMPRs are activated by BMPRII and subsequently activate the canonical SMAD-1/5/8-dependent and -independent signaling pathways. 17, 18 Interestingly, it has been shown that loss-of-function mutations of BMPRII are linked to primary pulmonary hypertension in humans, 19 demonstrating its importance in pulmonary artery biology and pathophysiology. However, it is unknown whether the genetic mutations or changes in BMPRII expression have any association with conduit arterial diseases, such as atherosclerosis.
We initially hypothesized that BMP4-induced endothelial inflammation would be mediated by BMPRII, and that its knockdown would prevent the BMP4 effect. However, we found a surprising, paradoxical result that loss of BMPRII in endothelial cells caused robust inflammation and atherosclerosis. Further studies showed that the proinflammatory effect of BMPRII knockdown was unique to this receptor member because knockdown of other BMP receptors did not induce endothelial inflammation. Moreover, we found that multiple proatherogenic factors, either individually or in combination, resulted in a common response, loss of BMPRII in endothelial cells in vitro and in vivo. We also found loss of BMPRII expression in human coronary arteries with advanced atherosclerotic lesions.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Loss of BMPRII Induces Endothelial Inflammation In Vitro and In Vivo
To examine whether BMPRII mediates BMP4-dependent endothelial inflammation, endothelial cells were treated with either BMPRII siRNA (BRII.si) or control siRNA (Non.si) in the presence or absence of BMP4, and monocyte adhesion assays were performed. As expected, BMP4 increased monocyte adhesion by 2-fold over siRNA control in human umbilical vein endothelial cells (HUVECs) ( Figure 1A) . To our surprise, however, knockdown of BMPRII markedly elevated basal monocyte adhesion by almost 5-fold over controls, independent of BMP4 ( Figure 1A) . To determine the underlying mechanisms for this unexpected result, expression of cell adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), BMP4, and BMPRII was examined in HUVECs. BMPRII siRNA reduced BMPRII expression by ≈90%, whereas ICAM-1 and VCAM-1 expression was increased by 6-and 3-fold, respectively, compared with nonsilencing control, but basal BMP4 expression was unaffected ( Figure 1B ; Figure IA in the online-only Data Supplement). We next investigated the effect of BMPRII knockdown on activation of the canonical BMP pathway by examining SMAD1/5/8 phosphorylation [20] [21] [22] in HUVECs. As expected, BMP4 treatment induced SMAD1/5/8 phosphorylation in a time-dependent manner, which was blocked by BMPRII siRNA ( Figure 1C ), consistent with a previous report. 23 This suggests that BMPRII siRNA effectively inhibits the canonical signaling pathway in response to BMP4, while paradoxically inducing endothelial inflammation.
We next tested whether this proinflammatory effect is specific to BMPRII knockdown. To compare the specificity of each BMP receptor, endothelial cells were treated with siRNAs specific for other BMP receptors (type I: Alk1, Alk2, Alk3, and Alk6 and type II: ActRIIa, ActRIIb, and BMPRII). Only BMPRII siRNA was able to induce ICAM-1 and VCAM-1 expression markedly above control siRNA levels, whereas all other BMP receptor siRNAs tested did not ( Figure 1D ). Interestingly, Alk1 knockdown decreased endothelial inflammation, which suggests that basal expression of ICAM-1 and VCAM-1 is mediated by ligands, such as BMPs or transforming growth factor-β, existing in the culture media. Also, Alk3 and Alk6, like Alk1 showed a moderate downregulation of ICAM-1 compared with the Non.si controls indicating that these receptors might mediate the proinflammatory effects attributable to these ligands, which may be present in the culture media or produced by the cells themselves. These findings suggest that specific loss of BMPRII, but not other BMP receptors, triggers an endothelial inflammatory response ( Figure 1D ; Figure ID -IF in the online-only Data Supplement).
To validate whether this unexpected in vitro finding was also relevant in vivo, we examined expression of ICAM-1 and VCAM-1 in arterial walls of BMPRII-deficient ApoE knockout mice (BMPRII +/− ApoE −/− ) in comparison with BMPRII +/+ ApoE −/− littermate control mice. Because homozygotic knockout of BMPRII causes embryonic lethal phenotype, 24 heterozygotic BMPRII +/− mice were used. To rule out the effect of high-fat diet on our experimental model, the mice used in the study were fed a standard chow diet. Expression of both ICAM-1 and VCAM-1 was significantly increased in the arterial endothelium of BMPRII +/− ApoE −/− compared with BMPRII +/+ ApoE −/− mice ( Figure 1E ; Figure IH in the onlineonly Data Supplement). These results suggest that specific BMPRII knockdown induces endothelial inflammation in a BMP4-independent manner both in vitro and in vivo.
Loss of BMPRII Induces Endothelial Inflammation by Mechanisms Mediated by Reactive Oxygen Species, NADPH Oxidase, and NFκB Activity
Next we studied the mechanisms by which BMPRII knockdown induces endothelial inflammation. Because reactive oxygen species (ROS) play an important role in endothelial inflammation and atherosclerosis, 6, 9 we tested whether the proinflammatory effect of BMPRII was mediated by ROS. Knockdown of BMPRII increased ROS production in HUVECs as measured by Amplex-Red. This increased ROS production was significantly blunted by the cell-permeable ROS scavenger polyethylene glycol catalase ( Figure IIA in the online-only Data Supplement), implicating a potential role for ROS in BMPRII-mediated endothelial inflammation.
Because Nox1 is a reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase member producing ROS involved in endothelial inflammation, 9 we tested the effect of apocynin (a NADPH oxidase inhibitor and ROS scavenger) 25 on BMPRII knockdown-induced inflammation in HUVECs. Treatment with apocynin significantly inhibited increased monocyte adhesion and ICAM-1 expression after BMPRII siRNA (Figure 2A and 2B; Figure IIB and IIC in the online-only Data Supplement). To validate these in vitro findings, we measured in vivo ROS production in the aortic walls of BMPRII +/− ApoE −/− and BMPRII +/+ ApoE −/− mice by dihydroethidium staining. 9 Increased ROS production was observed in the aortic wall, including endothelium (arrows in the inset) and smooth muscle cells of BMPRII +/− ApoE −/− compared with BMPRII +/+ ApoE −/− mice ( Figure 2C ). ROS production in the aortic endothelium coincided with Nox1 expression in BMPRII +/− ApoE −/− , which was not detected in BMPRII +/+ ApoE −/− mice ( Figure 2D ), indicating a potential link among BMPRII reduction, Nox1 induction, and ROS production in the arterial wall. This was further demonstrated in HUVECs, which showed that BMPRII knockdown induced Nox1 expression ( Figure IID in the online-only Data Supplement; Figure 2E ). Moreover, simultaneous knockdown of Nox1 and BMPRII significantly prevented VCAM-1 expression, but not ICAM-1, ( Figure 2E ; Figure Because induction of ICAM-1 and VCAM-1 is known to be regulated by nuclear factor-KappaB (NFκB), we tested the role of NFκB signaling pathway in BMPRII knockdown-induced endothelial inflammation. Treatment of HUVECs with the NFκB inhibitor BAY 11-7082 significantly inhibited monocyte adhesion, as well as ICAM-1 and VCAM-1 mRNA and protein expression induced by BMPRII knockdown (Figure 2F-2H; Figure IIF in the online-only Data Supplement). Collectively, these findings suggest that knockdown of BMPRII in endothelial cells stimulates NADPH oxidase and ROS production, which, in turn, mediates endothelial inflammatory responses, including ICAM-1 and VCAM-1 expression, and monocyte adhesion by a NFκB-dependent pathway.
BMPRII Deficiency Exacerbates Atherosclerosis Development in ApoE −/− mice
We then tested the hypothesis that BMPRII deficiency exacerbates atherosclerosis using acute and chronic mouse models. We compared atherosclerosis development in the carotid arteries of ApoE −/− mice using an acute partial ligation model of atherosclerosis as we recently described. 6, 7 As expected, partial ligation of left carotid artery (LCA) rapidly induced In A, cells were then treated with BMP4 (100 ng/mL; 4 hours), and THP1 monocyte adhesion to ECs was determined (mean±SEM; n=6; *P<0.05). In B, cells were lysed and analyzed by Western blot with antibodies to BMPRII, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), using β-actin as a loading control. In C, cells were treated with BMP4, and cell lysates were analyzed with phospho-smad1/5/8 or total smad1/5/8 antibodies, and the Western band intensities were quantified (*P<0.05; n=3). D, Human aortic endothelial cells transfected with siRNAs specific for BMPRII, Alk1, Alk2, Alk3, Alk6, ActRIIa, ActRIIb, or control (Non.si) were analyzed by Western blots with BMPRII, VCAM-1, and ICAM-1 antibodies. E, Representative images show immunostaining of frozen sections of thoracic aortas obtained from BMPRII +/− ApoE −/− and BMPRII +/+ ApoE −/− mice (n=6 each) using ICAM-1 and VCAM-1 antibodies (red). Nuclei stained with DAPI (blue) and auto-fluorescence signals showing elastic laminas are shown in green. L indicates lumen. atherosclerosis in BMPRII +/+ ApoE −/− by 2 weeks post ligation on a high-fat diet, whereas the contralateral right carotid artery remained lesion-free ( Figure 3A ). In comparison, BMPRII deficiency in BMPRII +/− ApoE −/− mice increased LCA lesion area by >5-fold compared with BMPRII +/+ ApoE −/− littermate controls ( Figure 3A and 3B ). Increased atherosclerosis in the BMPRII-deficient mice showed correlation with CD45+ leukocyte infiltration ( Figure III in the online-only Data Supplement), but was not attributable to exacerbated hypercholesterolemia, or abnormal serum lipid profiles compared with BMPRII +/+ ApoE −/− littermate controls ( Table I in the online-only Data Supplement). Next, chronic atherosclerosis development was examined in the aortic arches of BMPRII +/− ApoE −/− and BMPRII +/+ ApoE −/− mice fed a high-fat diet. Treatment with high-fat diet for 2 months induced atherosclerosis in the aortic arch of BMPRII +/+ ApoE −/− , as expected. In comparison, BMPRII deficiency increased plaque burden by 2-fold in BMPRII +/− ApoE −/− mice ( Figure 3C and 3D). These results obtained from the 2 different models of atherosclerosis strongly indicate that genetic haplodeficiency of BMPRII is sufficient to exacerbate atherosclerosis development.
BMPRII Expression Is Downregulated by Proatherogenic Risk Factors, While Upregulated by Antiatherogenic Conditions
We next asked whether BMPRII expression in arterial endothelium is regulated by conditions or stimuli relevant to pathophysiology of human atherosclerosis. Because atherosclerosis is caused by multiple risk factors, we hypothesized that various proatherogenic conditions, such as hypercholesterolemia, d-flow, hypertension, and proinflammatory cytokines, either individually or in combination, downregulate BMPRII expression, which, in turn, drives endothelial inflammation and atherosclerosis. We first tested whether BMPRII expression could be decreased by d-flow and hypercholesterolemia using our carotid partial ligation model of d-flow-induced atherosclerosis in ApoE −/− mice fed a high-fat diet ( Figure 4A ). 6, 26 Although we did not notice any remarkable change in the BMPRII expression at an early time point (2 days post ligation), BMPRII expression became undetectable in flow-disturbed LCA endothelium and was markedly reduced in smooth muscle cells at 1 week post ligation. In contrast, BMPRII expression in the contralateral right carotid artery remained relatively unchanged at the 1-week time point ( Figure IV in the online-only Data Supplement). These findings suggest that d-flow and hypercholesterolemia in combination downregulated BMPRII expression, whereas 1 week of hypercholesterolemia alone was not sufficient to decrease BMPRII level. Interestingly, we did not observe any BMPRII staining in the intima at 1 week post ligation ( Figure IV in the online-only Data Supplement), suggesting that the leukocytes infiltrating the intima at this time point, as we recently demonstrated, 26 do not express detectable level of BMPRII expression.
To determine whether flow itself could downregulate BMPRII expression in the arterial endothelium, endothelialenriched RNA was collected from the LCA and right carotid artery of C57Bl6 mice fed a chow diet at 48 hours post ligation as we previously described. 6, 7 BMPRII mRNA expression was decreased by >2-fold in the LCA endothelium compared with right carotid artery ( Figure 4B ). This was further demonstrated in HUVECs in vitro, which we exposed to unidirectional, laminar shear and oscillatory shear stress using a cone-and-plate shear device to mimic stable flow and d-flow in vivo, as we described previously. 8, 27 BMPRII expression was increased in HUVECs exposed to laminar shear compared with oscillatory shear stress and static control ( Figure 4C ). These findings further substantiate that proatherogenic d-flow downregulates, whereas antiatherogenic stable flow upregulates BMPRII expression in endothelial cells both in vivo and in vitro.
Next we tested whether angiotensin II (AngII), a key regulator of hypertension, and proinflammatory and proatherogenic agent, downregulates BMPRII expression in aortic endothelium. AngII infusion in C57BL/6 mice decreased BMPRII mRNA expression in a time-dependent manner, measured using endothelial-enriched RNA isolated from thoracic aortas at 36 to 72 hours post infusion ( Figure 4D ). Finally, we examined the role of proinflammatory cytokines using tumor necrosis factor α (TNFα) as a well-known prototypical cytokine that induces acute endothelial cell inflammation, 26,28 on BMPRII expression in HUVECs. TNFα significantly inhibited BMPRII expression in a concentration-and time-dependent manner ( Figure 4E ; Figure VA in the online-only Data Supplement). Conversely, we tested whether BMPRII expression could be upregulated or maintained by antiatherogenic stimuli. For this purpose, we chose statins as they are known to provide anti-inflammatory and antiatherogenic benefits in addition to their well-known lipid-lowering effect. 29, 30 Recently, simvastatin has been shown to upregulate the expression of BMPRII in different cell types in vitro, including lung microvascular endothelial cells. 31 Treatment of HUVECs with 3 different statins (simvastatin, rosuvastatin, and mevastatin) significantly increased BMPRII expression both at the mRNA and at the protein levels ( Figure 4F ; Figure VB -VD in the online-only Data Supplement). These results show that antiatherogenic conditions, such as stable flow and statin treatment, prevent the loss of BMPRII expression, whereas multiple proatherogenic conditions, including hypercholesterolemia, d-flow, AngII, and TNFα, downregulate BMPRII expression.
Loss of BMPRII in Human Coronary Arteries With Advanced Atherosclerotic Plaques
To examine whether our findings in in vitro settings and mouse models are relevant to human atherosclerosis, BMPRII expression was determined in human coronary arteries with atherosclerosis. Immunohistochemical staining showed that BMPRII expression was readily detected in nondiseased human coronary artery wall, including luminal endothelium and smooth muscle cells, but not in adventitia ( Figure 5A and 5B). However, BMPRII expression began to decrease (Figure 5Aii, 5Av, 5Bii, and 5Bv) in the coronary artery wall in early and intermediate lesions (type II-III) and was nearly undetectable (Figure 5Aiii , 5Avi, 5Biii, and 5Bvi) in advanced lesions (type V-VI). 32, 33 BMPRII staining was also not detected in intimal regions known to contain leukocyte accumulations, consistent with the above finding in mouse ( Figure 4A ). Overall, BMPRII expression in coronary artery endothelium showed a significant negative correlation (R 2 =0.68; n=14 patients) with atheroma intensity (Figure 5C ), suggesting that a similar relationship exists between BMPRII loss and atherosclerosis development in humans as demonstrated in our mouse models.
Overexpression of BMPRII Rescues Endothelial Inflammation Caused by BMPRII Knockdown
Next we tested whether we could reverse the BMPRII knockdown-induced endothelial inflammation by overexpressing BMPRII. To this end, we overexpressed BMPRII wild type or short form, lacking the C-terminal tail domain using adenoviral constructs in endothelial cells treated with BMPRII siRNA. Overexpression of BMPRII wild type, but not the short form, was able to blunt the endothelial expression of ICAM-1 and VCAM-1 induced by BMPRII knockdown (Figure 6A  and 6B ). This result suggests that the C-terminal tail region of BMPRII plays a critical role in regulating ICAM-1 and VCAM-1 expression in response to BMPRII knockdown.
Discussion
Our serendipitous finding that the loss of BMPRII induces endothelial inflammation and atherosclerosis came as a surprise at first because we initially hypothesized that knockdown of the receptor mediating BMP4 action would prevent endothelial inflammation. To the contrary, we found that knockdown of BMPRII in endothelial cells induced monocyte adhesion through the expression of ICAM-1 and VCAM-1 (Figure 1 ). This increase in the adhesion molecule expression and monocyte adhesion was independent of the BMP4 treatment indicating that BMPRII plays a critical role in endothelial inflammation, perhaps in a BMP ligand-independent manner. Further in vivo studies showed that loss of BMPRII induced endothelial inflammation (Figures 1 and 2) and atherosclerosis in BMPRII +/− ApoE −/− mice (Figure 3 ). Our data also showed that BMPRII expression was progressively lost as advanced atherosclerotic plaques formed in human coronary arteries ( Figure 5 ). The progressive loss of BMPRII was also found in our mouse model of atherosclerosis ( Figure 4A ). Together, these results suggest that loss of BMPRII may be a common event occurring both in human atherosclerosis and in mouse models of atherosclerosis.
Although our data on loss of BMPRII expression in human coronary arteries with advanced lesions need to be interpreted with caution because of the small number of tissue samples (n=14 patients) used in the study, it does raise the possibility that loss of BMPRII in atherosclerosis may be an important . Bone morphogenic protein receptors II (BMPRII) expression is reduced by proatherogenic risk factors, while upregulated by antiatherogenic conditions. A, ApoE −/− mice were partially ligated and fed the high-fat diet for 2 or 7 days. Frozen sections of ligated left carotid artery (LCA) exposed to disturbed flow were stained with platelet/endothelial cell adhesion molecule 1 (PECAM-1) or BMPRII antibody (red), and representative confocal microscopy images are shown (n=6). DAPI staining of nuclei (blue) and elastic laminas (green) are shown. Arrows and asterisk point to endothelial cells and intima leukocytes, respectively. B, Endothelial-enriched RNAs were isolated from right carotid artery (RCA) and LCA of C57Bl6 mice at 48-hours postpartial ligation, and BMPRII mRNA was determined by qPCR (n=4; *P<0.05). C, Human umbilical vein endothelial cells (HUVECs) were exposed to static control, laminar shear (LS), or oscillatory shear (OS) in vitro for 24 hours, and BMPRII expression was determined by qPCR (n=4; *P<0.05). D, Endothelial-enriched RNAs were isolated from thoracic aortas of C57Bl6 mice, after AngII infusion for 0 to 72 hours, and BMPRII was determined by qPCR (n=4; *P<0.05). E and F, HUVECs were treated with tumor necrosis factor-α (TNFα; E) or simvastatin or rosuvastatin for 24 hours (F). AngII indicates angiotensin II.
pathophysiological molecular event that has not been appreciated thus far. Although genomic mutations or downregulation of BMPRII has been linked to human primary pulmonary hypertension, 19 human secondary pulmonary hypertension, 34 and rat hypoxic pulmonary hypertension, 35 they have never been implicated in atherosclerosis. Primary pulmonary hypertension predominantly occurs in young women with a median age at diagnosis of 36.4 years. [36] [37] [38] [39] The rarity of the disease 19, 37, 38 and short survival duration (mean survival of 2.8 years) [40] [41] [42] [43] of these patients may explain why BMPRII has not been previously implicated in more common vascular diseases, such as atherosclerosis.
Our data indicate that seemingly disparate, multiple proatherogenic factors downregulate BMPRII expression through a potentially common pathway. For example, hypercholesterolemia, d-flow, the prohypertensive AngII, and the proinflammatory cytokine TNFα, all downregulated BMPRII expression in endothelial cells in vitro and in vivo (Figure 4) . One possibility is that these multiple proatherogenic risk factors converge on increased production of proinflammatory cytokines, such as TNFα, acting as common effectors. 44 These proinflammatory cytokines produced by vascular wall cells and infiltrating leukocytes under various proatherogenic conditions may downregulate BMPRII expression. In contrast, anti-inflammatory conditions, such as treatment with statins 31 or stable flow, increase or maintain BMPRII expression thereby preventing endothelial inflammation and atherosclerosis. BMPRII thus may serve as a common target of these pro-and antiatherogenic risk factors ( Figure 6C ).
We found that loss of BMPRII induced endothelial inflammation and atherosclerosis by the mechanisms mediated by NADPH oxidases, ROS production, and NFκB activation. How the loss of BMPRII triggers these signaling pathways needs to be further defined, but it may depend on cell types and biological context. 23 Interestingly, we were able to rescue endothelial inflammation caused by BMPRII knockdown by overexpressing BMPRII wild type, but not by the BMPRII short form. This suggests that the C-terminal tail domain of BMPRII plays a constitutive anti-inflammatory role and that its loss or reduction induces proinflammatory response. One potential mechanistic explanation for this is the unique "molecular docking" nature of the long cytoplasmic tail domain of BMPRII, which is not found in other members of transforming growth factor-β/BMP receptor superfamily. 45 The long cytoplasmic tail domain of BMPRII is known to bind various signaling proteins, including NFκB-p50 protein and cSrc. 46 Loss of the BMPRII, especially the C-terminal domain, may induce abnormal activation of these pathways, leading to NFκB activation and endothelial inflammation. Consistent with this idea, the proinflammatory effect of BMPRII knockdown was unique only to this receptor because knockdown of all other type I and type II BMP receptors examined in our study did not induce endothelial inflammation.
Other possibilities include that the loss of BMPRII may result in altered activation of non-BMP2/4 ligands, such as BMP6/7 and BMP9/10 families as well as Ttransforming growth factor-β, while inhibiting BMP2/4 pathway. In pulmonary artery smooth muscle cells, BMPRII deletion was shown to inhibit BMP2/4 signaling, while augmenting BMP6/7 pathway via activation of ActRIIa receptor. 23 However, knockdown of ActRIIa, which is the primary receptor for BMP6/7, 47 did not affect endothelial inflammation in our system, suggesting that endothelial inflammation caused by BMPRII knockdown is unlikely to be mediated by BMP6/7. BMP9 is known to be a vascular quiescence factor and binds to Alk1 and BMPRII along with a coreceptor. 48 However, our results showed that BMP9 and BMP10 neutralizing antibodies had no effect on endothelial inflammation caused by BMPRII knockdown, ruling out the potential role of these BMPs in our system (Figure VIA-VIC in the online-only Data Supplement). Further, we showed that knockdown of Alk1, which could mediate TGFβ effect, 49 did not increase endothelial inflammation ( Figure IF in the online-only Data Supplement). Together, these results suggest that endothelial inflammation induced by BMPRII reduction occurs in a ligand-independent manner.
We propose that multiple proatherogenic risk factors, such as hypercholesterolemia, hypertension, d-flow, and inflammatory conditions, either independently or in combination, downregulate BMPRII expression through a common mechanism ( Figure  6C ). Endothelial cells exposed to d-flow in athero-prone regions produce BMP4, which, in turn, induces an early endothelial inflammation resulting in intimal leukocytes infiltration. In the presence of additional risk factors, such as hypercholesterolemic conditions, these leukocytes, including macrophages and dendritic cells, become foam cells and produce proinflammatory cytokines. These cytokines, such as TNFα, and additional risk factors, including hypertensive AngII and d-flow, would then downregulate BMPRII, which triggers vicious cycle of inflammatory responses leading to atherosclerosis by the ROS and NFκB-dependent mechanisms ( Figure 6C ).
In conclusion, we show that BMPRII is a common target of multiple proatherogenic factors and that its loss in arterial wall induces endothelial inflammation and atherosclerosis. BMPRII may be a critical, anti-inflammatory, and antiatherogenic protein and may be used as a novel diagnostic and therapeutic target in atherosclerosis. Figure 6 . Endothelial inflammation induced by bone morphogenic protein receptors II (BMPRII) knockdown can be rescued by overexpressing BMPRII WT, but not by the BMPRII short form. A, Schematic of BMPRII WT and BMPRII short form, indicating the C-terminal FLAG tag in both constructs. B, Human umbilical vein endothelial cells treated with Non.si and BRII.si were further infected with adenoviral BMPRII WT or BMPRII short for 24 hours. Representative blots show expression of intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) with FLAG tagged BMPRII short form and BMPRII WT expression and β-actin as controls. The bar graph shows the quantification of ICAM-1 and VCAM-1 expression of Western blots (n=3; *P<0.05). C, The schematic shows summary and working hypothesis that proatherogenic conditions downregulate BMPRII expression, which, in turn, induces endothelial inflammation and atherosclerosis. Antiatherogenic conditions upregulate endothelial BMPRII expression. ROS indicates reactive oxygen species; and TNF, tumor necrosis factor.
